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Abstract 
Background: Little is known about the impact of sex on lung cancer patients from the psychological, economic and 
social perspectives. This study was designed to explore the psychosocial and economic impact according to sex of 
metastatic non‑small cell lung cancer (mNSCLC) in patients and caregivers.
Methods: Exploratory study of two cohorts of patients starting first‑line treatment for mNSCLC. The following 
questionnaires were administered at baseline, 4 months later and following the first and second disease progression: 
APGAR, relationship impact scale, DUKE‑UNC scale, economic impact in patients and caregiver, and Zarit scale. It was 
planned to include 1250 patients to get an 80% possibility of detecting as significant (p < 0.05) effect sizes less than 
0.19 between men and women. Univariate comparisons were made between the tests applied to men and women. 
Overall survival was estimated with Kaplan–Meier method. Cox analyses were done to estimate hazard ratios (HRs) 
with 95% CI.
Results: 333 patients were included. Most families reported to continue being functional despite the lung cancer 
diagnosis. Regardless of sex, they did not perceive changes in their partner relationship. Most patients felt their social 
support was normal. Roughly 25% of people reported a worsening in their economic situation, without remarkable 
differences by sex. Statistically significant differences were found between both groups regarding the caregiver’s 
relationship to the patient (more parents were the caregiver in females than in males, p < 0.0001) and the caregiver’s 
employment situation (more employed caregivers in females) (p < 0.0001). Most caregivers of both sexes considered 
that taking care of their relative did not pose a significant burden.
Conclusions: This study provides a preliminary insight into sex‑related characteristics in the management of 
advanced NSCLC and its impact on the emotional, social and economic burden of patients and their caregivers, and 
recall the high priority of researching in cancer from a sex perspective. Nevertheless, due to the low recruitment rate 
and the relevant loss of patients during the follow‑up, it was difficult to find differences by sex.
Trial registration: ClinicalTrials.gov identifier: NCT02336061.
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Background
Following the GLOBOCAN 2018 estimates of cancer 
worldwide incidence and mortality, in both sexes com-
bined, lung cancer is the most commonly diagnosed 
cancer (11.6% of the total cases) and the leading cause of 
cancer death (18.4% of the total cancer deaths) globally 
and among males, and the second in females [1]. Accord-
ing to data from the Spanish Statistics National Institute 
(INE), in 2017 there were a total of 22,089 (17,241 men 
and 4848 women) deaths in Spain due to lung cancer [2], 
which corresponds to a mortality rate of 71.38/100,000 
inhabitants (125.56/100,000 in men and 28.39/100,000 
inhabitants in women) [3].
About 80% of lung cancers are non-small cell lung can-
cer (NSCLC) and around 40% of patients have metastatic 
disease at the time of diagnosis [4].
Historically, lung cancer has been viewed as a male 
disease, but during the past years there has been a dra-
matic increase in the incidence in women, attributed to 
a significant increase in tobacco consumption; indeed, 
according to the last inform from the Spanish Asso-
ciation Against Cancer [5], the percentage of smoking 
women is approaching to that in men (18% vs. 27%). As 
the incidence of lung cancer in women has increased, sig-
nificant sex-based differences in epidemiology, biology, 
and treatment responses have become evident [6, 7]. In 
spite of it, little is known about the impact of sex in lung 
cancer patients from the psychological, economic and 
social perspectives [8].
Cancer research and clinical trials have historically 
focused on efficacy parameters, toxicity and quality of 
life. However, there is an increasing interest to evaluat-
ing the disease’s impact from other perspectives such as 
caregivers, family functionality and finances, both in the 
patients and their family setting.
At the time of disease progression, the burden of symp-
toms and the problems related to social and caregivers 
support become more evident. Similarly, the economic 
resources can be also influenced [9]. It is expected that 
some patients become more dependent, require more 
resources and time from caregivers. Eventually, caregiv-
ers have to reduce their working hours or seek for addi-
tional help. The caregiver role in Spain has traditionally 
assigned to family, usually women [10] but now that 
lung cancer is no longer considered a men’s disease, little 
is known about the influence of sex´s patients from the 
caregivers’ perspective. Around 20–50% caregivers suffer 
from stress, including changes in their usual routines, 
changes in family roles, personal health conditions, and 
occupational and financial disruption [11].
Lung cancer seems to have a greater economic impact 
than other tumors, due to its poor prognosis and the sig-
nificance of its symptoms, which can lead to incapacity 
for the patient (and occasionally the caregiver) in con-
tinuing to perform their job role [12]. Most caregivers 
of patients with NSCLC suffer financial and social harm 
from the patient’s diagnosis as their social and leisure 
activities are reduced and they are forced to reduce their 
working hours [13]. The economic costs associated with 
the disease are due to the large number of symptoms 
presented by these patients and their severity, increasing 
with the progression of the disease and deterioration in 
the quality of life. There are no data published to date on 
the overall cost of the disease in Spain.
The present study aimed to explore the differences 
in the influence lung cancer has on women compared 




This study is a multicenter, prospective, observational, 
epidemiological, follow-up exploratory study of two 
cohorts of patients with metastatic NSCLC (male and 
female), carried out by the Spanish Association for Lung 
Cancer Research in Women (ICAPEM).
Patient selection
Eligible patients were ≥ 18  years old, had cytological or 
histologically confirmed metastatic NSCLC, an East-
ern Cooperative Oncology Group performance status 
(ECOG PS) ≤ 3 and no previous systemic treatment for 
metastatic NSCLC.
Patients meeting all selection criteria who were going 
to start first-line treatment for metastatic NSCLC were 
included in the study. The treatment chosen during the 
study depended on the oncologist’s judgment. No treat-
ment recommendations or restrictions were stated in the 
study protocol.
Evaluations during the study
Information on the demographic variables, medical his-
tory, social and economic impact was collected. All the 
patients’ clinical information (including assessment of 
Ethics committee: Comité Ético de Investigación Clínica del Hospital Clínic de Barcelona, Spain. Reference number: 
HCB/2014/0705.
Keywords: Carcinoma, Non‑small‑cell lung, Caregivers, Sex characteristics
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treatment response) was recorded in the correspond-
ing medical records of the investigator, obtained as part 
of routine care, together with responses to the various 
questionnaires administered to the patient and their pri-
mary caregiver (Table  1). All questionnaires were filled 
in baseline, 3–4 months later (at the time of first tumor 
evaluation) and following the first and second disease 
progression. In order to evaluate family functionality, 
the validated Spanish version of the APGAR question-
naire was used [14]. The Family APGAR was developed 
in 1978 [15], and it is a 5-item questionnaire (with each 
item rates on a 3-point scale) measuring five constructs 
(adaptability, partnership, growth, affection, and resolve). 
The validated Spanish version of Duke-UNC-11 scale 
was used to measure each individual’s perception of the 
degree and type of social support available/received [16]. 
The caregiver burden in this study was assessed using the 
22-item Zarit scale, which presents 22 items expressed 
as statements on how people who take care of a patient 
feel: the caregiver must select the statement that best 
suits how they feel. It uses a 5-point scale from 0 (never) 
to 4 (almost always), with a higher score indicating a 
higher burden. This scale has been validated in Spain by 
Martin et al. [17]. To assess the impact of the disease on 
the economy of patients and their caregivers, an ad-hoc 
designed questionnaire based on other previously pub-
lished [18, 19] was used.
Clinical procedures for tumor evaluation and assess-
ment of the response to treatment were conducted in 
accordance with the site’s usual practice. Patients were 
followed until the patient’s death was documented or up 
to a maximum of 24 months after the end of treatment.
Statistical analysis
Approximately 1250 patients were planned to be 
included. With this size, there was an 80% possibility of 
detecting as significant (p < 0.05) effect sizes less than 
0.19 between men and women. The effect size serves to 
make the differences or relationships between differ-
ent variables with different values comparable, thereby 
allowing us to measure the strength of the relationship 
between two variables. According to the Cohen classi-
fication, which defined Cohen’s d [20] for quantitative 
variables, a difference is considered to be large when 
the effect size is greater than 0.8, medium if it is greater 
than 0.5 and small if it is greater than 0.2 [21]. In this 
study, 0.19 was taken as a reference, which should ena-
ble us to detect small to large figures as significant.
Descriptive tables of the baseline and demographic 
characteristics of the patients are presented, as well as 
the results obtained from the self-administered ques-
tionnaires. All patients’ clinical and tumor characteris-
tics at the time of diagnosis of the metastatic advanced 
disease were provided.
Univariate comparisons were made between the tests 
applied to men and women. In the case of quantitative 
variables, the Student’s t-test was used. Overall survival 
was estimated with Kaplan–Meier method. Median 
survival times with 95% confidence intervals (CI) were 
calculated. Cox analyses were done to estimate hazard 
ratios (HRs) with 95% CI.
All statistical tests were two-sided. The significance 
level was established at a value of α = 0.05. The statisti-
cal analyses were performed using SAS version 9.4.
Results
Between February 2015 and February 2017, 333 patients 
(229 men and 104 women) from 20 Spanish hospitals 
were included.The study was prematurely closed due 
to a low recruitment rate. Most of demographic and 
baseline patients’ characteristics were similar between 
female and male (Table  2), with only significant dif-
ferences in the number of smokers/former-smokers 
(97% of male and 63% of female, p = 0.0001) and the 
proportion of married/partnered (73% of male and 
49% of female, p = 0.0002). 217 men and 85 women 
received chemotherapy as first line treatment, 7 men 
and 19 women were treated with EGFR TKI inhibitors, 
4 men and 5 women received an ALK TKI inhibitor, 
and 1 man and 2 women received immune checkpoint 
inhibitors. 78 out of 104 men and 29 out of 39 women 
reported second-line treatment: docetaxel was the most 
administered drug (20 men and 9 women), followed by 
nivolumab (20 men and 7 women).
The 15-monhts overall survival (OS) was 56% (95% CI 
45.4–65.9%) and 37% (95% CI 30.3–44.1%) for female 
and male, respectively, p = 0.0034. The median OS 
was also longer in women but did not reach statistical 
Table 1 Psychosocial and  economic status 
assessment questionnaires (see these questionnaires 
on the “Additional files”)
a Score: 7–10 functional; 4–6 moderately dysfunctional; 0–3 severely 
dysfunctional
b Score: ≥ 32, normal support; < 32, low support
c Score: ≤ 46, no burden; > 46 and < 56, slight burden; ≥ 56: intense burden
Order Patient Caregiver
1 Family impact scale: APGAR a Caregiver economic impact 
scale
2 Relationship impact scale Caregiver burden scale:  ZARITc
3 Socio‑affective impact scale 
(perceived support): DUKE‑
UNCb
4 Patient economic impact scale
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significance (17.1 vs 11.0  months, HR 0.732 (95% CI 
0.534–1.005), p = 0.0524) (Fig. 1).
Main baseline responses to the study questionnaires 
by patients and their caregivers are summarized in 
Tables  3 and 4. Most families were considered func-
tional (high score in APGAR questionnaire: 83% of men 
and women) and, those who had a partner said their 
relationship had not changed (69% of men and 61% of 
women) or even had improved (27% of men and 39% 
of women). 77% of men (177/229) and 82% of women 
(85/104) thought their social support was normal. 
According to the patients’ economic questionnaire, 132 
of the 195 men and 43 of the 96 women who answered 
the questionnaire, were retired at the beginning of the 
study. Around a quarter of interviewed people said 
their economic situation was a little worse than before 
suffering the disease, without remarkable differences by 
sex.
Statistically significant differences were found 
between both groups regarding the caregiver’s rela-
tionship to the patient, with more parents being the 
caregiver in females than in males (p < 0.0001), and the 
caregiver’s employment situation (more employed car-
egivers for female patients, p < 0.0001) (Table 4). 60% of 
caregivers of male patients (38/63) and 76% of caregiv-
ers of female who answered the economic question-
naire and who were working, had not changed their 
working hours. More than 80% of caregivers of both 
sexes who answered the Zarit questionnaire, consid-
ered that taking care of their relative did not pose a sig-
nificant burden (Table 4).
Due to the relevant loss of patients during the fol-
low-up, it was difficult to find differences by sex in 
the responses to the different questionnaires. Accord-
ing to the family APGAR questionnaire, most families 
remained functional across the study (Additional file 1: 
Online Resource 1): mean functionality levels were 
similar in men and women over time. The relation-
ship with the partner did not change or improved dur-
ing the course of the disease in a vast majority of men 
and women. The social support of the patient (Duke-
UNC-11 scale) remained normal throughout the study, 
without appreciable differences between mean social 
support scores in both sexes (Additional file 2: Online 
Resource 2). The vast majority of patients considered 
the disease did not affect their household finances 
across the study, although a quarter of interviewed 
patients reported a minimum negative economic 
impact after lung cancer diagnosis, without remark-
able differences by sex. No remarkable differences were 
found between the mean caregiver’s burden (Zarit 
scale) across the study by sex (Additional file 3: Online 
Resource 3), nor in the economic evaluations.
Table 2 Baseline characteristics of patients
Italic values are statistically significant
a EGFR mutation status was not determined in 67 men (29%) and 8 (8%) 
women; ALK mutation status was not determined in 103 men (45%) and 26 
(25%) women; BRAF mutation status was not determined in 200 men (87%) and 
93 (90%) women
b Wilcoxon signed-rank test
c Fisher’s exact test
d Chi-squared test
Parameter Arm A Arm B p value
(Male) (Female)
(N = 229) (N = 104)
n % n %
Age, years 0.0010b
 Mean (SD) 65 (8.8) 62 (10.4)
 Median (Q1, Q3) 66 (60, 72) 61 (55, 69)
 Range 36–84 37–85
Comorbidities 0.2809b
 Mean (SD) 3 (2.1) 3 (2.1)
 Median (Q1, Q3) 2 (1, 4) 2 (1, 4)
 Range 1–10 1–10
ECOG 0.1643c
 0 91 40 29 28
 1 107 47 60 58
 2 23 9 10 9
 3 2 1 1 1
 Missing 6 3 4 4
Smoking habits < 0.0001d
 Smoker/ex‑smoker 222 97 66 63
 Non‑smoker 7 3 38 37
Marital status 0.0002c
 Single 25 11 19 18
 Married/Partnered 168 73 51 49
 Widowed 9 4 13 13
 Divorced 4 2 6 6
 Missing 23 10 15 14
Educational level 0.0098c
 No education 25 11 9 9
 Basic 118 52 37 35
 Higher 31 13 26 25
 Missing 55 24 32 31
Histology 0.0082c
 Adenocarcinoma 158 69 87 84
 Squamous cell 44 19 8 8
 Others 27 12 8 8
Mutationsa
 EGFR+ 11 5 21 20
 ALK+ 4 2 5 5
 BRAF+ 1 1 1 1
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Discussion
The Association for Lung Cancer Research in Women 
(ICAPEM) published a consensus paper in 2017 where a 
detailed analysis of the sex perspective in lung cancer was 
done [8]. One of the main conclusions was that there was 
a lack of information about evaluating social, economic 
and emotional impact on women with lung cancer and 
their caregivers/relatives. This study was set up to doing a 
first approach to this issue.
To the best of our knowledge, this is the first longi-
tudinal study to investigate the impact of advanced 
lung cancer on patients and their caregivers from a 
sex perspective. As expected [22, 23] there were more 
smokers/ex-smokers men than women (38 out of 104 
diagnosed women have never smoked). Also, there were 
more men than women with a partner. As reported in 
previous studies [24–27], median survival to 15 months 
and overall survival were longer in women than in 
men. Several reasons have been proposed to explain 
the improved survival of women with NSCLC, such as 
smoking history, comorbidities, different driver muta-
tion pattern or differences in histology. In this study 
women were more likely than men to have adenocar-
cinoma. While some studies showed that women with 
adenocarcinoma had better outcomes than women with 
squamous cell carcinoma [28, 29], others have seen that 
women had better disease-free survival and OS than 
men regardless of stage, smoking status and histology 
[7, 30]. Therefore, at present, the reasons why women 
with NSCLC live significantly longer than men remain 
elusive [8].
The presence of no-relative caregivers was anecdotic 
in both groups, as has been reported in most of studies 
[31–33]. More men than women had their partners as 
caregivers, and more women than men had their par-
ents as caregivers. In most of studies, partners were the 
most frequent family caregivers of cancer patients [13, 
34, 35], mainly spouses, probably due to the social role 
that women still adopt. In a similar way, more family 
caregivers of female patients were employed, while the 
Female Male Parameter p-value
N 99 227
Events 54 (54.5%) 135 (59.5%)
Censored 45 (45.5%) 92 (40.5%)
Median 17.1 95% CI (11.5-24.1) 11.0 95% CI (9.3-13.6) Log-Rank: 3.764 HR: 0.732 95% CI (0.534-1.005) LR:0.0524
HR:0.0535
at 15           
months





























Fig. 1 Survival by sex
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percentage of family caregivers of female patients being 
home-maker was anecdotic.
A large majority of caregivers of both sexes reported 
that taking care of their relative did not pose a signifi-
cant baseline burden. Findings from previous studies 
in this area pointed that caregivers of cancer patients 
experienced a high level of burden [13, 36–38]. This 
apparent discrepancy might be due to the interpreta-
tion of the Zarit Burden Inventory in Spain [39]. This 
questionnaire uses a 5-point scale from 0 (never) to 4 
(almost always), with a higher score indicating a higher 
burden. In Spain, a score ≤ 46 is considered as “No bur-
den”, 47–55 “light burden” and ≥ 56 “Intense burden”. 
As stated by Ribé et al. [40], those cut points probably 
derive from the results of the scale validation study in 
Spain, carried out in a psychogeriatric centre, with-
out considering whether it was useful and valid in any 
group of caregivers regardless of the characteristics of 
the person they care for. However, other studies con-
sider a score of 24 as the cut-off score to identify car-
egivers with possible mental distress who were in need 
of further assessment and continued intervention, fol-
lowing the interpretation of Schreiner et al. [41].
No differences by sex were found throughout the study 
in family functionality, nor perception of social sup-
port, but around a quarter of interviewed patients said 
their economic situation was a little worse after the lung 
Table 3 Baseline responses to  the  study questionnaires: 
patients
a Score obtained for the question “How has your relationship with your partner 
changed during the last month?” This item only applies to patients who have 
a partner (134/157 men who answered that question and 46/63 women who 
answered that question)
b Score obtained for the question “Has the disease you suffer from affected your 
household finances in any way?” This item only applies to patients who have 
a partner (134/157 men who answered that question and 46/63 women who 
answered that question)
c Fisher’s exact test
Parameter Arm A Arm B p  valuec
(Male) (Female)
(N = 229) (N = 104)
n % n %
Family functionality (APGAR) 0.6961
 Functional 190 83 86 83
 Moderately dysfunctional 10 4 5 5
 Severely dysfunctional 2 1 2 2
 Missing 27 12 11 10
Partner  relationshipa 0.3235
 n 137 – 46 –
 Improved 37 27 18 39
 Worsened 3 2 0 0
 Not changed 94 69 28 61
 Missing 3 2 0 0
Social support (DUKE) 0.5372
 Normal 177 77 85 82
 Low 7 3 5 5
 Missing 45 20 14 13
Economic  situationb 0.3476
 Better 0 0 1 1
 The same 121 53 49 47
 A little bit worse 55 24 29 28
 Much worse 18 8 10 10
 Missing 35 15 15 14
Table 4 Baseline responses to  the  study questionnaires: 
patients’ caregivers
a This question applies only to family members
b This question applies only to those not hired by the patient
c Score: ≤ 46 no burden; 47–55 slight burden; ≥ 56 intense burden
Parameter Arm A Arm B
(Male patients) (Female 
patients)
(N = 229) (N = 104)
n % n %
Relationship to the patient
 Parents 23 10 25 24
 Partner 141 62 45 43
 Brother/sister 13 6 6 6
 Other family member 1 1 2 2
 No relative 6 2 5 5
 Missing 45 19 21 20
Work situation of the  relativea
 Retired 55 24 26 25
 Self‑employed 10 4 6 6
 Employed 39 17 35 33
 Unemployment benefits 8 4 4 4
 Home‑maker 44 19 2 2
 No income 10 4 4 4
 Missing 63 28 27 26
Changes in working  hoursb
 No 38 17 25 24
 Change in the schedule 17 7 12 12
 Reduced 0 0 5 4
 Stop working 8 4 3 3
 Missing 166 72 59 57
Caregiving burden (Zarit scale)c
 No burden 116 51 54 52
 Slight burden 19 8 7 7
 Intense burden 10 4 4 4
 Missing 84 37 39 37
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cancer diagnosis, without remarkable differences by 
sex. In addition, no remarkable differences were found 
between the mean caregiver’s burden across the study by 
sex. Nevertheless, the high loss of patients and caregivers’ 
responses to the questionnaires during the study, limited 
the statistical power for detecting significant changes/dif-
ferences in outcomes.
Other limitations of this study and directions for future 
research should be noted. First, as it was not possible 
to reach the planned sample size, the statistical power 
for detecting significant correlates of study outcomes is 
limited: indeed, with the final sample size we reached, 
our study only have a power of 0.44 to detect as signifi-
cant (p < 0.05) an OR of 1.4 (or its equivalent effect size 
of 0.19). Therefore, these results should be interpreted 
in an exploratory way to raise hypotheses that should 
be addressed in subsequent studies. Second, as stated 
above, the longitudinal design of the study led to the 
loss of a significant number of patients and caregivers 
who responded to the questionnaires in subsequent vis-
its. Some of those could be due to a natural selection of 
patients with a better prognosis and, therefore, with a 
longer survival; in addition, we cannot rule out that some 
patients with a worse prognosis died before the first eval-
uation, which was performed 3–4 months after inclusion, 
at the time of the first tumor evaluation (usual practice). 
It is highly recommended to do a thorough monitoring 
of this kind of studies and to use recapture strategies 
such as telephone calls after each visit. Third, Spain has a 
National Healthcare System that covers the main costs of 
diseases, including treatments (pharmacological and oth-
ers), hospitalisation, outpatient visits and tests. In addi-
tion, the low percentage of people who acknowledged 
that their economic situation had worsened due to the 
disease, may also be related to the Mediterranean culture, 
where it is not appropriate to talk about money.
Conclusion
Despite its limitations, the present study provides a pre-
liminary insight into sex-related characteristics in the 
management of advanced NSCLC and its impact on the 
emotional, social and economic burden of patients and 
their caregivers, and recall the high priority of research-
ing in cancer from a sex perspective.
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